KTTA logo

Pasithea Therapeutics (KTTA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 September 2021

Indexes:

Not included

Description:

Pasithea Therapeutics (KTTA) is a biotechnology company focused on developing innovative treatments for mental health disorders. They aim to create new therapies that target the underlying causes of conditions like depression and anxiety, improving patients' quality of life through advanced research and development.

Events Calendar

Earnings

Next earnings date:

May 14, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 30, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 02, 2024

Analyst ratings

Recent major analysts updates

10 July '23 EF Hutton
Buy
03 Apr '23 EF Hutton
Buy
14 Dec '21 EF Hutton
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
KTTA
globenewswire.com09 September 2024

Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
KTTA
globenewswire.com03 September 2024

Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.

Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
KTTA
InvestorPlace13 December 2023

Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tuesday up less than 1%.

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
KTTA
GlobeNewsWire07 September 2023

-- Attendees may request 1 x 1 meeting with management at [email protected] --  PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.

FAQ

  • What is the primary business of Pasithea Therapeutics?
  • What is the ticker symbol for Pasithea Therapeutics?
  • Does Pasithea Therapeutics pay dividends?
  • What sector is Pasithea Therapeutics in?
  • What industry is Pasithea Therapeutics in?
  • What country is Pasithea Therapeutics based in?
  • When did Pasithea Therapeutics go public?
  • Is Pasithea Therapeutics in the S&P 500?
  • Is Pasithea Therapeutics in the NASDAQ 100?
  • Is Pasithea Therapeutics in the Dow Jones?
  • When was Pasithea Therapeutics's last earnings report?
  • When does Pasithea Therapeutics report earnings?
  • Should I buy Pasithea Therapeutics stock now?

What is the primary business of Pasithea Therapeutics?

Pasithea Therapeutics (KTTA) is a biotechnology company focused on developing innovative treatments for mental health disorders. They aim to create new therapies that target the underlying causes of conditions like depression and anxiety, improving patients' quality of life through advanced research and development.

What is the ticker symbol for Pasithea Therapeutics?

The ticker symbol for Pasithea Therapeutics is NASDAQ:KTTA

Does Pasithea Therapeutics pay dividends?

No, Pasithea Therapeutics does not pay dividends

What sector is Pasithea Therapeutics in?

Pasithea Therapeutics is in the Healthcare sector

What industry is Pasithea Therapeutics in?

Pasithea Therapeutics is in the Biotechnology industry

What country is Pasithea Therapeutics based in?

Pasithea Therapeutics is headquartered in United States

When did Pasithea Therapeutics go public?

Pasithea Therapeutics's initial public offering (IPO) was on 15 September 2021

Is Pasithea Therapeutics in the S&P 500?

No, Pasithea Therapeutics is not included in the S&P 500 index

Is Pasithea Therapeutics in the NASDAQ 100?

No, Pasithea Therapeutics is not included in the NASDAQ 100 index

Is Pasithea Therapeutics in the Dow Jones?

No, Pasithea Therapeutics is not included in the Dow Jones index

When was Pasithea Therapeutics's last earnings report?

Pasithea Therapeutics's most recent earnings report was on 13 November 2024

When does Pasithea Therapeutics report earnings?

The next expected earnings date for Pasithea Therapeutics is 14 May 2025

Should I buy Pasithea Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions